Anti-Diarrheal Medicines Improve Tolerability of Nerlynx in Breast Cancer Patients

Anti-Diarrheal Medicines Improve Tolerability of Nerlynx in Breast Cancer Patients
Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide (brand name Imodium A-D, among others) and other anti-diarrheal medications reduces the severity and duration of this complication, improving treatment tolerability, according to findings from a Phase 2 clinical trial. Results from the CONTROL trial (NCT02400476) were shared earlier this month in Chicago, Illinois, at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, in a poster titled “Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.Puma Biotechnology's Nerlynx is an oral medicine that works by blocking the action of several proteins that promote cell growth, including epidermal growth factor receptors (EGFRs) and human epidermal growth factor receptor 2 (HER2). In a prior Phase 3 trial, called ExteNET trial (NCT00878709), Nerlynx was tested as an extended adjuvant (secondary) treatment for early-stage, HER2-positive breast cancer patients who had receive
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.